Drug intelligence / Profile preview

Lycofertilic

Development stage: Unknown
Lead developer: Lycotec
Administration: Oral

Overview

Lycofertilic is an oral female fertility support supplement developed by Lycotec and launched by Cambridge Diagnostic Imaging for reproductive health use. It is described as a daily nutraceutical formulation intended to support fertility, with reported use of carotenoids to support tissue oxygenation and ingredient groups aimed at modulating inflammation and oxidative stress related to ovarian function. Public descriptions also note inclusion of algae-derived docosahexaenoic acid omega-3 and positioning around support for ovarian reserve and preconception reproductive wellness. It is marketed as a nutritional supplement rather than a pharmaceutical medicine, and a separate related product, Lycofertilic Prime, is positioned specifically for IVF and egg retrieval preparation.

Brand names: Lycofertilic

Beyond the preview

Go deeper on Lycofertilic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lycofertilic.

Explore the full profile